Peripheral T-cell lymphomas: A review of current approaches and hopes for the future

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Skarbnik, Alan P ^a   Burki, Meher ^a   Pro, Barbara ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ALCL; Alisertib; Bortezomib; Brentuximab; Pralatrexate; PTCL; Romidepsin; Zanolimumab

Indexed keywords

ALEMTUZUMAB; ALISERTIB; BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEHYDRODIDEMNIN B; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FORODESINE; GEMCITABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MOGAMULIZUMAB; NELARABINE; PRALATREXATE; PREDNISONE; ROMIDEPSIN; UNINDEXED DRUG; VINCRISTINE; ZANOLIMUMAB;

APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEATH; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERYTHROPHAGOCYTOSIS; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PANCYTOPENIA; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RELAPSE; REVIEW; RISK; UNSPECIFIED SIDE EFFECT;

EID: 84891076403     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00138     Document Type: Review

References (71)

1. Beitinjaneh, A., Saliba, R. M., Okoroji, G.-J., Korbling, M., Alousi, A. M., Popat, U., et al. (2011). Autologous and allogeneic stem cell transplantation for T-cell lymphoma: the M.D. Anderson Cancer Center experience. ASH Annual Meeting Abstracts, San Diego, Vol. 118, :4118.
2. Broussais-Guillaumot, F., Coso, D., Belmecheri, N., Ivanov, V., de Collela, J. M., Aurran-Schleinitz, T., et al. (2013). Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution. Leuk. Lymphoma doi:10.3109/10428194.2013.776680. [Epub ahead of print].
3. Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., et al. (2012). Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30, 631-636. doi:10.1200/JCO.2011.37.4223
4. Corradini, P., Tarella, C., Zallio, F., Dodero, A., Zanni, M., Valagussa, P., et al. (2006). Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20, 1533-1538. doi:10.1038/sj.leu.2404306
5. Cress, W. D., and Seto, E. (2000). Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184, 1-16. doi:10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
6. Czuczman, M. S., Porcu, P., Johnson, J., Niedzwiecki, D., Kelly, M., Hsi, E. D., et al. (2007). Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk. Lymphoma 48, 97-103. doi:10.1080/10428190600961058
7. Damaj, G., Gressin, R., Bouabdallah, K., Cartron, G., Choufi, B., Gyan, E., et al. (2013). Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J. Clin. Oncol. 31, 104-110. doi:10.1200/JCO.2012.43.7285
8. d'Amore, F., Radford, J., Relander, T., Jerkeman, M., Tilly, H., Osterborg, A., et al. (2010). Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br. J. Haematol. 150, 565-573. doi:10.1111/j.1365-2141
9. d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., et al. (2012). Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J. Clin. Oncol. 30, 3093-3099. doi:10.1200/JCO.2011.40.2719
10. Dang, N. H., Pro, B., Hagemeister, F. B., Samaniego, F., Jones, D., Samuels, B. I., et al. (2007). Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol. 136, 439-447. doi:10.1111/j.1365-2141.2006.06457.x
11. Dueck, G., Chua, N., Prasad, A., Finch, D., Stewart, D., White, D., et al. (2010). Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116, 4541-4548. doi:10.1002/cncr.25377
12. Duvic, M., Forero-Torres, A., Foss, F., Olsen, E., and Kim, Y. (2007). Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study. ASH Annual Meeting Abstracts, Atlanta, Vol. 110, :122.
13. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A. P., Repp, R., et al. (2004). A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103, 2920-2924. doi:10.1182/blood-2003-10-3389
14. Escalon, M. P., Liu, N. S., Yang, Y., Hess, M., Walker, P. L., Smith, T. L., et al. (2005). Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103, 2091-2098. doi:10.1002/cncr.20999
15. Feyler, S., Prince, H. M., Pearce, R., Towlson, K., Nivison-Smith, I., Schey, S., et al. (2007). The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 40, 443-450. doi:10.1038/sj.bmt.1705752
16. Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M. R., et al. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk. Lymphoma. [Epub ahead of print]. doi:10.3109/10428194.2012.742521
17. Friedberg, J., Mahadevan, D., Jung, J., Persky, D. O., Lossos, I. S., Danaee, H., et al. (2011). Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B-and T-cell non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts, San Diego, Vol. 118, :95.
18. Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M. R., Tucci, A., et al. (2007). Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110, 2316-2323. doi:10.1182/blood-2007-02-074641 doi:10.1182/blood-2009-05-221275
19. Gascoyne, R. D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B. F., Greiner, T. C., et al. (1999). Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93, 3913-3921.
20. Horwitz, S., Moskowitz, C., Kewalramani, T., Hamlin, P., Straus, D., O'Connor, O., et al. (2005). Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat. ASH Annual Meeting Abstracts, Atlanta, Vol. 106, :2679.
21. Huang, Y., de Reynies, A., de Leval, L., Ghazi, B., Martin-Garcia, N., Travert, M., et al. (2010). Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115, 1226-1237.
22. Ikezoe, T., Takeuchi, T., Yang, J., Adachi, Y., Nishioka, C., Furihata, M., et al. (2009). Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab. Invest. 89, 1364-1373. doi:10.1038/labinvest.2009.106
23. Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., et al. (2012). Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 30, 837-842. doi:10.1200/JCO.2011.37.3472
24. Jantunen, E., Wiklund, T., Juvonen, E., Putkonen, M., Lehtinen, T., Kuittinen, O., et al. (2004). Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 33, 405-410. doi:10.1038/sj.bmt.1704367
25. Kanagal-Shamanna, R., Lehman, N. L., O'Donnell, J. P., Lim, M. S., Schultz, D. S., Chitale, D. A., et al. (2013). Differential expression of aurora-A kinase in T-cell lymphomas. Mod. Pathol. 26, 640-647. doi:10.1038/modpathol.2012.211
26. Kanakry, J. A., Kasamon, Y. L., Gocke, C. D., Tsai, H. L., Davis-Sproul, J., Ghosh, N., et al. (2013). Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol. Blood Marrow Transplant. 19, 602-606. doi:10.1016/j.bbmt.2013.01.006
27. Kicska, G. A., Long, L., Horig, H., Fairchild, C., Tyler, P. C., Furneaux, R. H., et al. (2001). Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 98, 4593-4598. doi:10.1073/pnas.071050798
28. Kim, M. K., Kim, S., Lee, S. S., Sym, S. J., Lee, D. H., Jang, S., et al. (2007a). High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann. Hematol. 86, 435-442. doi:10.1007/s00277-007-0254-1
29. Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., et al. (2007b). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109, 4655-4662. doi:10.1182/blood-2006-12-062877
30. Kim, S. J., Yoon, D. H., Kang, H. J., Kim, J. S., Park, S. K., Kim, H. J., et al. (2012). Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur. J. Cancer 48, 3223-3231. doi:10.1016/j.ejca.2012.06.003
31. Kyriakou, C., Canals, C., Goldstone, A., Caballero, D., Metzner, B., Kobbe, G., et al. (2008). High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 26, 218-224. doi:10.1200/JCO.2007.12.6219
32. Le Gouill, S., Milpied, N., Buzyn, A., De Latour, R. P., Vernant, J. P., Mohty, M., et al. (2008). Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J. Clin. Oncol. 26, 2264-2271. doi:10.1200/JCO.2007.14.1366
33. Lee, J., Suh, C., Kang, H. J., Ryoo, B. Y., Huh, J., Ko, Y. H., et al. (2008). Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann. Oncol. 19, 2079-2083. doi:10.1093/annonc/mdn431
34. Mahadevan, D., Spier, C., Della Croce, K., Miller, S., George, B., Riley, C., et al. (2005). Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol. Cancer Ther. 4, 1867-1879. doi:10.1158/1535-7163.MCT-05-0146
35. Mercadal, S., Briones, J., Xicoy, B., Pedro, C., Escoda, L., Estany, C., et al. (2008). Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann. Oncol. 19, 958-963. doi:10.1093/annonc/mdn022
36. Mourad, N., Mounier, N., Briere, J., Raffoux, E., Delmer, A., Feller, A., et al. (2008). Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111, 4463-4470. doi:10.1182/blood-2007-08-105759
37. Mulford, D. A., Pohlman, B. L., Hamlin, P. A., Young, F., Pamer, E., and Horwitz, S. M. (2010). A Phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas. J. Clin. Oncol. 28(Suppl. 15), 8046. [Meeting Abstracts].
38. O'Connor, O. A., Horwitz, S., Hamlin, P., Portlock, C., Moskowitz, C. H., Sarasohn, D., et al. (2009). Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol. 27, 4357-4364. doi:10.1200/JCO.2008.20.8470
39. O'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., et al. (2011). Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29, 1182-1189. doi:10.1200/JCO.2010
40. O'Mahony, D., Morris, J. C., Moses, L., O'Hagan, D., Gao, W., Stetler-Stevenson, M., et al. (2005). Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. ASH Annual Meeting Abstracts, Atlanta, Vol. 106, :3353.
41. O'Mahony, D., Morris, J. C., Stetler-Stevenson, M., Matthews, H., Brown, M. R., Fleisher, T., et al. (2009). EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin. Cancer Res. 15, 2514-2522. doi:10.1158/1078-0432.CCR-08-1254
42. Ottmann, O. G., Spencer, A., Prince, H. M., Bhalla, K. N., Fischer, T., Liu, A., et al. (2008). Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH Annual Meeting Abstracts, San Francisco, Vol. 112, :958.
43. Piccaluga, P. P., Agostinelli, C., Califano, A., Rossi, M., Basso, K., Zupo, S., et al. (2007). Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 117, 823-834. doi:10.1172/JCI26833
44. Piccaluga, P. P., Agostinelli, C., Zinzani, P. L., Baccarani, M., Dalla Favera, R., and Pileri, S. A. (2005). Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol. 6, 440. doi:10.1016/S1470-2045(05)70213-8
45. Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., et al. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117, 5827-5834. doi:10.1182/blood-2010-10-312603 doi:10.1182/blood.V98.9.2865
46. Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., et al. (2001). Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98, 2865-2868. doi:10.1182/blood.V98.9.2865
47. Piva, R., Agnelli, L., Pellegrino, E., Todoerti, K., Grosso, V., Tamagno, I., et al. (2010). Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J. Clin. Oncol. 28, 1583-1590. doi:10.1200/JCO.2008.20.9759
48. Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., et al. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190-2196. doi:10.1200/JCO.2011.38.0402
49. Qi, W., Spier, C., Liu, X., Agarwal, A., Cooke, L. S., Persky, D. O., et al. (2013). Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk. Res. 37, 434-439. doi:10.1016/j.leukres.2012.10.017
50. Reimer, P., Rudiger, T., Geissinger, E., Weissinger, F., Nerl, C., Schmitz, N., et al. (2009). Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27, 106-113. doi:10.1200/JCO.2008.17.4870
51. Ribrag, V., Caballero, D., Ferme, C., Zucca, E., Arranz, R., Briones, J., et al. (2013). Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica 98, 357-363. doi:10.3324/haematol.2012.069757
52. Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., Leon, A., Marin, J., et al. (2007a). The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann. Oncol. 18, 652-657. doi:10.1093/annonc/mdl466
53. Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., Leon, A., Marin, J., et al. (2007b). Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur. J. Haematol. 79, 32-38. doi:10.1111/j.1600-0609.2007.00856.x
54. Sallah, S., Wehbie, R., Lepera, P., Sallah, W., and Bobzien, W. (1999). The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Br. J. Haematol. 104, 163-165. doi:10.1046/j.1365-2141.1999.01139.x
55. Santini, V., Gozzini, A., and Ferrari, G. (2007). Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr. Drug Metab. 8, 383-393. doi:10.2174/138920007780655397
56. Savage, K. J. (2007). Peripheral T-cell lymphomas. Blood Rev. 21, 201-216. doi:10.1016/j.blre.2007.03.001
57. Savage, K. J., Chhanabhai, M., Gascoyne, R. D., and Connors, J. M. (2004). Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol. 15, 1467-1475. doi:10.1093/annonc/mdh392
58. Schetelig, J., Fetscher, S., Reichle, A., Berdel, W. E., Beguin, Y., Brunet, S., et al. (2003). Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88, 1272-1278.
59. Schmitz, N., Trumper, L., Ziepert, M., Nickelsen, M., Ho, A. D., Metzner, B., et al. (2010). Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116, 3418-3425. doi:10.1182/blood-2010-02-270785
60. Smith, S., Burns, L. J., van Besien, K., LeRademacher, J., He, W., Laport, G. G., et al. (2010). Autologous (auto) versus allogeneic (allo) hematopoietic cell transplantation (HCT) for T-NHL: a CIBMTR analysis. ASH Annual Meeting Abstracts, Orlando, Vol. 116, :689.
61. Swerdlow, S. H. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer.
62. Vose, J., Armitage, J., and Weisenburger, D. (2008). International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124-4130. doi:10.1200/JCO.2008.16.4558
63. Wang, E. S., O'Connor, O., She, Y., Zelenetz, A. D., Sirotnak, F. M., and Moore, M. A. (2003). Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma 44, 1027-1035. doi:10.1080/1042819031000077124
64. William, B. M., Hohenstein, M., Loberiza, F. R. Jr., Caponetti, G. C., Bociek, R. G., Bierman, P., et al. (2010). Phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts, Orlando, Vol. 116, :288.
65. Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., et al. (2010). Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28, 1591-1598. doi:10.1200/JCO.2009.25.3575
66. Yang, D. H., Kim, W. S., Kim, S. J., Bae, S. H., Kim, S. H., Kim, I. H., et al. (2009). Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol. Blood Marrow Transplant. 15, 118-125.
67. Zain, J., O'Connor, O., Zinzani, P. L., Norman, A., and de Nully Brown, P. (2010). Multicenter, open-label trial of PXD 101 in patients with relapsed/refractory peripheral T-cell lymphoma. J. Clin. Oncol. 28(Suppl.), abstr. :e18565.
68. Zinzani, P. L., Alinari, L., Tani, M., Fina, M., Pileri, S., and Baccarani, M. (2005). Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90, 702-703.
69. Zinzani, P. L., Magagnoli, M., Bendandi, M., Orcioni, G. F., Gherlinzoni, F., Albertini, P., et al. (1998). Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann. Oncol. 9, 1351-1353. doi:10.1023/A:1008409601731
70. Zinzani, P. L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., et al. (2007). Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 4293-4297. doi:10.1200/JCO.2007.11.4207
71. Zinzani, P. L., Venturini, F., Stefoni, V., Fina, M., Pellegrini, C., Derenzini, E., et al. (2010). Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann. Oncol. 21, 860-863. doi:10.1093/annonc/mdp508